(Q33588554)

28 July 2017

1 reference

title

Troglitazone: a review of its use in the management of type 2 diabetes mellitus (English)

1 reference

28 July 2017

0 references

G L Plosker

1

1 reference

28 July 2017

D Faulds

series ordinal

2

1 reference

28 July 2017

publication date

1 March 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

57

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

409-438

1 reference

Troglitazone, a new antidiabetic agent, decreases cyclosporine level

28 July 2017

cites work

1 reference

12 December 2020

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus

1 reference

12 December 2020

Possible troglitazone-warfarin interaction

1 reference

12 December 2020

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

12 December 2020

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

12 December 2020

Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats

1 reference

12 December 2020

Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency

1 reference

12 December 2020

Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome

1 reference

12 December 2020

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction

1 reference

12 December 2020

Prevalence and secular trends in obesity in Pacific and Indian Ocean island populations

1 reference

12 December 2020

Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects

1 reference

12 December 2020

Troglitazone for non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Troglitazone ameliorates insulin resistance in patients with Werner's syndrome

1 reference

12 December 2020

Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice

1 reference

12 December 2020

New therapeutic agents for the treatment of NIDDM.

1 reference

12 December 2020

Epidemiology of type II diabetes: an international perspective

1 reference

12 December 2020

Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.

1 reference

12 December 2020

Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.

1 reference

12 December 2020

PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes

1 reference

12 December 2020

Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes

1 reference

12 December 2020

TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone

1 reference

12 December 2020

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.

1 reference

12 December 2020

Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells

1 reference

12 December 2020

"Glitazones", a prospect for non-insulin-dependent diabetes

1 reference

12 December 2020

Oral antidiabetic drug use in the elderly

1 reference

12 December 2020

Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.

1 reference

12 December 2020

Is troglitazone a real indication for obese subjects with impaired glucose tolerance?

1 reference

12 December 2020

Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis

1 reference

12 December 2020

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

1 reference

12 December 2020

Amelioration of hyperglycemia in streptozotocin-induced diabetic rats receiving a marginal mass of islet grafts by troglitazone, an oral antidiabetic agent

1 reference

12 December 2020

Treatment of dyslipoproteinaemia in diabetes mellitus

1 reference

12 December 2020

Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.

1 reference

12 December 2020

Ten-year follow-up of Japanese overweight subjects with impaired glucose tolerance: identification of a diabetes-prone subpopulation

1 reference

12 December 2020

Effect of troglitazone on steady-state pharmacokinetics of digoxin

1 reference

12 December 2020

Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.

1 reference

12 December 2020

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

1 reference

12 December 2020

Acute effects of troglitazone on in vivo insulin action in normal rats.

1 reference

12 December 2020

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

12 December 2020

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice

1 reference

12 December 2020

Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.

1 reference

12 December 2020

Predicting future diabetes in Latino women with gestational diabetes. Utility of early postpartum glucose tolerance testing

1 reference

12 December 2020

Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers

1 reference

12 December 2020

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

12 December 2020

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

1 reference

12 December 2020

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

12 December 2020

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

12 December 2020

Fatal hepatotoxicity associated with troglitazone

1 reference

12 December 2020

Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.

1 reference

12 December 2020

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

1 reference

12 December 2020

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

1 reference

12 December 2020

Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.

1 reference

12 December 2020

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

12 December 2020

Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients.

1 reference

12 December 2020

Concomitant administration of cholestyramine influences the absorption of troglitazone

1 reference

12 December 2020

Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London.

1 reference

12 December 2020

Impaired glucose tolerance in the U.S. population.

1 reference

12 December 2020

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

1 reference

12 December 2020

Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb

1 reference

12 December 2020

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

1 reference

12 December 2020

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

12 December 2020

Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction

1 reference

12 December 2020

Costs of diabetes in Texas, 1992.

1 reference

12 December 2020

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

1 reference

12 December 2020

Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells

1 reference

12 December 2020

Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention

1 reference

12 December 2020

Effect of troglitazone on cyclosporine whole blood levels

1 reference

12 December 2020

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food

1 reference

12 December 2020

Troglitazone has a scavenging effect on reactive oxygen species

1 reference

12 December 2020

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

1 reference

12 December 2020

Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice

1 reference

12 December 2020

Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.

1 reference

12 December 2020

Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol

1 reference

12 December 2020

Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro

1 reference

12 December 2020

Potential interaction of troglitazone and cyclosporine

1 reference

12 December 2020

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

12 December 2020

Pharmacologic treatment options for non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

1 reference

12 December 2020

Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.

1 reference

12 December 2020

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

12 December 2020

Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.

1 reference

12 December 2020

Rezulin (troglitazone) greatly increases cyclosporine metabolism

1 reference

12 December 2020

Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm

1 reference

12 December 2020

Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety

1 reference

12 December 2020

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma

1 reference

12 December 2020

Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs.

1 reference

12 December 2020

Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment

1 reference

12 December 2020

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

12 December 2020

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

12 December 2020

Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited

1 reference

12 December 2020

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

12 December 2020

10.2165/00003495-199957030-00014

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1008120466

0 references

1 reference